JP2023506691A5 - - Google Patents

Info

Publication number
JP2023506691A5
JP2023506691A5 JP2022528124A JP2022528124A JP2023506691A5 JP 2023506691 A5 JP2023506691 A5 JP 2023506691A5 JP 2022528124 A JP2022528124 A JP 2022528124A JP 2022528124 A JP2022528124 A JP 2022528124A JP 2023506691 A5 JP2023506691 A5 JP 2023506691A5
Authority
JP
Japan
Prior art keywords
group
pharmaceutically acceptable
acceptable salt
compound
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022528124A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023506691A (ja
JP7473642B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/128597 external-priority patent/WO2021093839A1/zh
Publication of JP2023506691A publication Critical patent/JP2023506691A/ja
Publication of JP2023506691A5 publication Critical patent/JP2023506691A5/ja
Application granted granted Critical
Publication of JP7473642B2 publication Critical patent/JP7473642B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022528124A 2019-11-13 2020-11-13 Btk阻害剤としてのピロロピリミジン系化合物およびその使用 Active JP7473642B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN201911109773.2 2019-11-13
CN201911109773 2019-11-13
CN201911288492 2019-12-13
CN201911288492.8 2019-12-13
CN202010096582.3 2020-02-17
CN202010096582 2020-02-17
CN202010711270.9 2020-07-22
CN202010711270 2020-07-22
PCT/CN2020/128597 WO2021093839A1 (zh) 2019-11-13 2020-11-13 作为btk抑制剂的吡咯并嘧啶类化合物及其应用

Publications (3)

Publication Number Publication Date
JP2023506691A JP2023506691A (ja) 2023-02-20
JP2023506691A5 true JP2023506691A5 (cg-RX-API-DMAC7.html) 2023-02-28
JP7473642B2 JP7473642B2 (ja) 2024-04-23

Family

ID=75912541

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022528124A Active JP7473642B2 (ja) 2019-11-13 2020-11-13 Btk阻害剤としてのピロロピリミジン系化合物およびその使用

Country Status (6)

Country Link
US (1) US12378253B2 (cg-RX-API-DMAC7.html)
EP (1) EP4059935A4 (cg-RX-API-DMAC7.html)
JP (1) JP7473642B2 (cg-RX-API-DMAC7.html)
KR (1) KR102793446B1 (cg-RX-API-DMAC7.html)
CN (2) CN114728974B (cg-RX-API-DMAC7.html)
WO (1) WO2021093839A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4234558A4 (en) * 2020-12-07 2024-10-23 Zhejiang Longcharm Bio-Tech Pharma. Co., Ltd. PYRROLOPYRIDINE COMPOUND AND APPLICATION THEREOF
CN114761410B (zh) * 2021-04-06 2023-08-25 广州必贝特医药股份有限公司 吡咯并嘧啶酮类化合物及其应用
JP7645573B2 (ja) * 2021-05-12 2025-03-14 ジャージアン・ロングチャーム・バイオ-テック・ファーマ・カンパニー・リミテッド ピロロピリミジン類化合物の結晶形およびその調製方法
CN117500806A (zh) * 2021-05-28 2024-02-02 默沙东有限责任公司 Btk抑制剂及其中间体的合成
EP4448523A1 (en) 2021-12-14 2024-10-23 Crossfire Oncology Holding B.V. Macrocyclic btk inhibitors
CN115894500B (zh) * 2022-11-02 2024-05-28 中国药科大学 一种作为btk激酶抑制剂的化合物及其制备方法与用途
CN118702697A (zh) * 2023-03-18 2024-09-27 山东新时代药业有限公司 苯甲酰基吡咯并嘧啶类衍生物及其用途和制备方法
CN116375715B (zh) * 2023-04-06 2025-04-04 中国药科大学 一种作为非共价btk激酶抑制剂的化合物及其生物用途
WO2024246287A1 (en) 2023-06-02 2024-12-05 Crossfire Oncology Holding B.V. Medical use of a macrocyclic reversible btk inhibitor
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024256568A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Salt and crystal forms of a macrocyclic btk inhibitor
WO2024256574A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Process for preparing macrocyclic btk inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI398252B (zh) * 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
HRP20170311T1 (hr) * 2012-08-06 2017-04-21 Acea Biosciences Inc. Novi spojevi pirolopirimidina kao inhibitori protein kinaza
EP3042903B1 (en) * 2015-01-06 2019-08-14 Impetis Biosciences Ltd. Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
AU2015417922B2 (en) 2015-12-23 2018-12-20 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
AU2017315343A1 (en) 2016-08-24 2019-02-28 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof

Similar Documents

Publication Publication Date Title
WO2025067459A2 (en) Therapies for the treatment of cancer
US20220194946A1 (en) Fgfr inhibitors and methods of making and using the same
CN107382966B (zh) 一类荜茇酰胺-川芎嗪杂合物、制备方法及医药用途
CN114516857A (zh) Hpk1抑制剂及其用途
JP7830540B2 (ja) d-アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス
US20100087458A1 (en) Method of treating melanoma
CN117083265A (zh) 激酶抑制剂及其用途
JPH05163148A (ja) 抗腫瘍剤
KR20220124739A (ko) 암의 치료를 위한 병용 요법
JP2002527518A (ja) 新規なプテリン抗新生物薬
CN119745884A (zh) 一种用于治疗非小细胞肺癌的丙酮酸盐制剂及其制备方法
JP7664429B2 (ja) Fgfr4選択的阻害剤の塩及びその製造方法と用途
CN115260107B (zh) 一种抗肿瘤药物前药、药物组合物及在肿瘤靶向治疗领域的应用
US6037357A (en) N-benzoyl-α-alkylated azatyrosines as anticancer agents
JP2007510751A (ja) 新規化合物、対応する組成物、調製方法および/または治療方法
CN120774918A (zh) 蛋白降解剂类化合物及其制备方法、药物组合物和应用
JP7509340B2 (ja) トリゴネリンベースの化合物
CN118525012A (zh) 奥希替尼共晶及制备方法以及作为药物或在药物制剂中的应用
CN118994161B (zh) 一种(s)-2-(4-(4-甲基-1-哌嗪基)苯胺基)-8-苯胺基-9-(3-哌啶基)-9h-嘌呤及其应用
CN106146612B (zh) 一类乙二醛酶i不可逆抑制剂及其制备方法和用途
EP3956287B1 (en) Prodrugs of monomethyl fumarate
JPH0132826B2 (cg-RX-API-DMAC7.html)
CN113527331B (zh) 硝基咪唑类衍生物及其制备方法和用途
RU2200157C2 (ru) Пиридинкарбоксамидины, способ их получения и фармацевтическая композиция на их основе
TWI324516B (en) Fused tri-heterocyclic compounds